The rising trend of gastrointestinal (GI) cancer has become a global burden due to its aggressive nature and poor prognosis. Long noncoding RNAs (lncRNAs) have recently been reported to be overexpressed in different GI cancers and may contribute to cancer progression and chemoresistance. They are featured with more than 200 nucleotides, commonly polyadenylated, and lacking an open reading frame. LncRNAs, particularly urothelial carcinoma-associated 1 (UCA1), are oncogenes involved in regulating cancer progression, such as cell proliferation, invasion, migration, and chemoresistance, particularly in GI cancer. This review was aimed to present an updated focus on the molecular regulatory roles and patterns of lncRNA UCA1 in progression and chemoresistance of different GI cancers, as well as deciphering the underlying mechanisms and its interactions with key molecules involved, together with a brief presentation on its diagnostic and prognostic values. The regulatory roles of lncRNA UCA1 are implicated in esophageal cancer, gastric cancer, pancreatic cancer, hepatobiliary cancer, and colorectal cancer, where they shared similar molecular mechanisms in regulating cancer phenotypes and chemoresistance. Comparatively, gastric cancer is the most intensively studied type in GI cancer. LncRNA UCA1 is implicated in biological roles of different GI cancers via interactions with various molecules, particularly microRNAs, and signaling pathways. In conclusion, lncRNA UCA1 is a potential molecular target for GI cancer, which may lead to the development of a novel chemotherapeutic agent. Hence, it also acts as a potential diagnostic and prognostic marker for GI cancer patients.
22 September 2020 in Future Journal of Pharmaceutical Sciences
Background: Chenopodium album (Family: Amaranthaceae) is a nutritive herb mainly found in Bangladesh and had reported that it is having different bioactive phytochemicals including polyphenols. It has a great popularity for it is traditionally used as a medicine against microorganisms, inflammation, and cancer. We designed this experiment to explore the in vivo anticancer effects of C. album leaf extract against Ehrlich ascites carcinoma (EAC) cells in Swiss albino mice. Results: Administration of C. album leaf extract at concentration 200 (mg/kg) and 400 (mg/kg) showed 30.60% and 41.80% cell growth inhibition respectively that were statistically significant (***P < 0.001) and may lead to apoptosis, and the number of apoptotic cells were 37.5 ± 6.22, 54.67 ± 4.76 respectively (***P < 0.001). Plant extract at concentration 200 (mg/kg) and 400 (mg/kg) increased life span 22.27% and 51.07% respectively. Tumor weight decreased 18.50 ± 2.59 g, 13.67 ± 2.25 g respectively compared to the control group, and results were statistically significant (***P < 0.001). Treatment with plant extract 200 (mg/kg) and 400 (mg/kg) restored all biochemical parameters including hemoglobin content, white blood cell (WBC) count, and red blood cell (RBC) count of EAC cells bearing Swiss albino mice. Conclusion: Our current findings may suggest that C. album leaf extract showed potent anticancer activity through cell growth inhibition and apoptosis, increased mean survival time, decreased tumor weight, and restored all the biochemical parameters and stimulation of host immunity. As a result, the C. album leaf has taken into consideration as a potent source of bioactive compounds in cancer chemotherapy.
1 December 2020 in Biochemistry and Biophysics Reports
Breast cancer ranked second among most frequent cancer in the world playing a significant role in mortality rate. Having prior knowledge on differentially expressed genes in breast cell carcinoma elucidated important indications to understand the molecular mechanism underneath breast carcinogenesis. In this study we have investigated the distinguished CSN1S1 expression in human breast cancer. We have analyzed CSN1S1 mRNA expression between cancer and normal tissues using TCGA datasets. Moreover, analysis including promoter methylation, mutations, prognosis, co-expression, gene ontology, and pathways of CSN1S1 were performed by the TCGA Wanderer, UCSC Xena, cBioPortal, PrognoScan, UALCAN, and Enricher server. We have observed low mRNA expression and high promoter methylation of CSN1S1 in cancer tissues compared to normal tissues. Furthermore, we have also identified low mRNA expression in clinicopathological patients, as well as 9 deleterious mutations with highly co-expressed protein MRC1, and significantly related signaling pathways. We have found a positive correlation between the lower expression of CSN1S1 and patients surviving with breast cancer. Here we have concluded that CSN1S1 acts as a biomarker for the surveillance and prognosis of breast cancer, and also works as a novel therapeutic target at the molecular and pathway levels.
1 January 2018 in Journal of Pharmaceutical Research International
Objective: Traditionally Ficus hispida is used as a palliative for pain, inflammation, diabetes, fever and neurological disorders. The present study set out to evaluate the antinociceptive, anti-pyretic and anti-inflammatory activity of the methanolic extract of Ficus hispida leaves (MFHL). Methods: Pithy dried leaves of Ficus hispida were extracted with sufficient amount of pure methanol. The antinociceptive activity of MFHL was evaluated by using formalin induced paw licking, acetic acid-induced writhing, tail immersion and hot plate methods in Swiss albino mice. Its anti-pyretic activity was evaluated by Brewer's yeast-induced pyrexia test. And anti-inflammatory activity was assessed by using xylene-induced ear edema test. Results: The crude extract was found to have significant (p<0.05, vs. control) analgesic activity at the oral dose of 200 & 400 mg/kg b. wt., in the tested animals. Extract at dose of 200 mg/kg and 400 mg/kg significantly (p<0.05, vs. control) reduced paw licking and abdominal writhing of mice, and revealed significant increase in latency (p<0.05, vs. control) in tail immersion and hot plate test at 30 and 60 min after their administration. In Brewer's yeast-induced pyrexia test, the methanolic extract at the dose of 200 mg/kg and 400 mg/kg significantly (p<0.05, vs. control) reduced hyperthermia in mice in 1 hour observation and also lowering of temperature from 2 hours to 4 hours observation period respectively. In anti-inflammatory test, 200 mg/kg and 400 mg/kg of extract exhibited significant (p<0.05, vs. control) ear weight differences and inhibition of ear edema. Conclusion: Results of above study indicate that Ficus hispida leaves can be a potential source of analgesic, antipyretic and anti-inflammatory medication.
COVID-19 has raised significant concern regarding its neurological impact, particularly during the early pandemic waves when severe systemic inflammation and neuroimmune dysregulation were more common. Although SARS-CoV-2 has been extensively studied, the precise mechanisms underlying its neurological effects remain incompletely understood, and much of the available evidence is derived from early variants with higher pathogenicity. Current research indicates that neuroinflammatory processes—driven primarily by systemic cytokine elevation, microglial activation, and blood–brain barrier dysfunction—contribute to a wide range of neurological symptoms. Severe complications such as encephalopathy, stroke, and cognitive impairment were predominantly reported in critically ill patients infected with the Wuhan, Alpha, or Delta variants, while such manifestations are considerably less frequent in the Omicron era. Most proposed mechanisms, including ACE2-mediated viral entry into the central nervous system, are supported mainly by experimental or preclinical studies rather than definitive human evidence. Biomarkers such as IL-6 and TNF-α, along with neuroimaging modalities including MRI and PET, offer useful but indirect indicators of neuroinflammation. Therapeutic approaches continue to focus on controlling systemic inflammation through immunomodulatory agents, complemented by targeted non-pharmacological strategies—such as physical rehabilitation, cognitive support, and psychological interventions—for the minority of patients with persistent neurological deficits. Overall, current evidence supports a variant-dependent neuroinflammatory profile and underscores the need for longitudinal, mechanism-focused studies to better characterize long-term neurological outcomes and refine therapeutic strategies.
Protein arginine methyltransferase 5 (PRMT5) is a promising anticancer target, yet existing inhibitors shown limited clinical efficacy. Here, we paired multi-omics pan-cancer profiling with a machine learning virtual screening pipeline. Bioinformatics analyses with TIMER3, GEPIA2, UALCAN/CPTAC, the Human Protein Atlas, cBioPortal, STRING and Enrichr revealed widespread of PRMT5 mRNA expression, protein abundance, survival, genetic alteration, immune infiltration and co-expression networks with tumor-specific prognostic impact in GBM, LGG and KIRC. A deep neural network screened about 1.5 million PubChem compounds and deep neural network reached a ROC-AUC = 0.9857 and prioritized three candidates, CID 44345182, CID 2794188 and CID 44345334. Subsequent molecular docking against PRMT5 (PDB ID: 4X61), ADMET filtering and toxicity prediction, and 100 ns molecular dynamics (MD) simulations identified CID 44345182 as the potential hit, similar the docking scores of −9.8 compared with - 9.2 kcal/mol for the reference ligand in binding affinity and trajectory stability. These findings clarify the context-dependent roles of PRMT5 and further experiment validations are needed to establish CID 44345182 as a promising candidate.